FDA delays approval for BMS cancer therapy

Bristol-Myers said the marketing application submitted to the U.S. FDA for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Wang S, Miao Z, Yang Q, Wang Y, Zhang J Abstract Colon cancer is still one of the most common causes of cancer in human and is characterized by lymphocyte infiltrates and originates from the epithelial cells found in the lining of colon or rectum of the gastrointestinal tract. Mesenchymal stem cells (MSCs) are composed of the multipotent stem cell group of stroma and can be differentiated as various cell lineages, such as fibroblasts, osteoblasts, and adipocytes. MSCs provide mechanical and structural support and have potential functions during tumor growth and metastasis. The efficacy of MSC-based therapi...
Source: Canadian Journal of Gastroenterology - Category: Gastroenterology Tags: Can J Gastroenterol Hepatol Source Type: research
The hypothalamic-pituitary-thyroid axis is a common site of unintended, acquired disease either during or after the treatment of cancer. Children treated with external radiation therapy are at the highest risk for developing a thyroid-related late effect, but thyroid dysfunction and second primary thyroid neoplasms can also occur after treatment with radiopharmaceutical agents such as131I-metaiodobenzylguanidine. Increasingly recognized is the development of early thyroid dysfunction as an off-target consequence of the more novel cancer therapeutics such as the tyrosine kinase inhibitors and immune checkpoint inhibitors. T...
Source: Hormone Research in Paediatrics - Category: Endocrinology Source Type: research
Conclusion: Our results revealed that the presence of CIMP independently predicts poor OS in patients with stage IV CRC.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 December 2018Source: Journal of Geriatric OncologyAuthor(s): Andrea Sitlinger, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, Gretchen G. KimmickAbstractObjectiveTo explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer.MethodsEligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N = 107) complete...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Publication date: Available online 13 December 2018Source: Redox BiologyAuthor(s): Matilda Lee, Jayshree L. Hirpara, Jie-Qing Eu, Gautam Sethi, Lingzhi Wang, Boon-Cher Goh, Andrea L. WongAbstractDrug resistance invariably limits the response of oncogene-addicted cancer cells to targeted therapy. The upregulation of signal transducer and activator of transcription 3 (STAT3) has been implicated as a mechanism of drug resistance in a range of oncogene-addicted cancers. However, the development of inhibitors against STAT3 has been fraught with challenges such as poor delivery or lack of specificity. Clinical experience with sm...
Source: Redox Biology - Category: Biology Source Type: research
ConclusionsThe emergence of new drugs for mCRPC has improved treatment options dramatically. Currently, systemic treatment options for mCRPC include hormonal therapy, chemotherapy, immunotherapy, and radionuclide therapy as well as bone-modifying agents and palliative or supportive measures. Further, new genetically targeted agents (PARP inhibitors and PD-1 inhibitors) are on the horizon for certain subsets of biomarker-selected patients. The best strategies for patient selection and optimal sequential use to achieve the longest cumulative survival improvement and to prevent early resistance remain unclear.Patient summaryT...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Authors: Mendoza TR Abstract Cancer therapies are toxic. Newer oncological treatments such as immunotherapy produce unconventional adverse events that are collectively referred to as immune-related adverse events (irAEs). These irAEs are clinician-rated and typically reported via tabulation of adverse events from the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). However, the symptomatic effects of treatment and the severity of disease are best reported by the patient themselves. Although many pivotal trials for immunotherapeutic agents include health-related quality-of-life mea...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Publication date: 1 March 2019Source: Materials Letters, Volume 238Author(s): Qi Mai, Suqin Shen, Yifu Liu, Cui Tang, Chunhua YinAbstractDoxorubicin (DOX) is one of the commonly used chemotherapeutic agents, but its clinical use is restricted by systemic toxicity and tumor multidrug resistance. To overcome these barriers, PEG modified trimethyl chitosan based nanoparticles (NPs) were prepared for the coencapsulation and codelivery of DOX and survivin shRNA-expressing plasmid (iSur-pDNA). These NPs with particle sizes of 181.9 nm and zeta potentials of 20.2 mV exhibited a pH-sensitive release of DOX and a sustained rele...
Source: Materials Letters - Category: Materials Science Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Marketing | Pharmaceuticals | Yervoy